Please login to the form below

Not currently logged in
Email:
Password:

Nycomed and Orion in Easyhaler deal

Nycomed has agreed a deal with Orion Corporation for the co-marketing of Easyhaler combination products for the treatment of asthma and chronic obstructive pulmonary disease (COPD)

Nycomed has entered into an agreement with Orion Corporation for the co-marketing of Easyhaler combination products for the treatment of asthma and COPD in the major European countries, and an exclusive license and distribution arrangement for the Middle East and North Africa region (MENA). 

Orion is developing a budesonide-formoterol formulation that combines budesonide as an anti-inflammatory agent and formoterol as a long-acting bronchodilator. Orion has another Easyhaler research programme in progress to develop a fluticasone-salmeterol formulation. In this formulation fluticasone acts as an anti-inflammatory agent and salmeterol acts as a long-acting bronchodilator. 

The co-marketing area – in which both companies present their own product brands under the Easyhaler umbrella brand – covers the major European countries including Austria, the Benelux countries, France, Germany, Greece, Italy, Poland, Portugal, Spain and Switzerland. Orion will retain exclusive marketing rights for the Nordic countries, the UK and Eastern Europe, where the company is currently promoting single molecule Easyhaler products. Orion will exclusively manufacture the Easyhaler combination products covered by the agreement.

Dr. Liisa Hurme, senior vice-president of Orion's proprietary products division, said: “The collaboration creates a momentum for Easyhaler products in Europe and strengthens Orion's strategic objective to become a stronger player in the field of respiratory medication.”

Guido Oelkers, executive vice-president of commercial operations, Nycomed, added: “We see great potential in these high-quality Easyhaler products in major European countries and the MENA region. They will significantly enhance Nycomed's fast-growing Respiratory portfolio.”

8th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics